Background New vessel formation plays a pivotal role in the pathogenesis of neovascular-related diseases. Endothelial progenitor cells (EPCs) were found to contribute to neovascular-related diseases and interference with EPC neovascularization may be a novel target for these diseases. Zoledronate (Zol) was reported to exhibit anti-angiogenic effect. Basing on these evidences, we proposed that Zol may affect EPC function to exert novel anti-angiogenic effect. In this study, we therefore investigated the effects of Zol on multiple aspects of EPC function and explored the underlying mechanisms involved. Methodology/Principal Findings EPCs were cultured from bone marrow derived mononuclear cells. The potential effects of Zol on Angiotensin II (Ang II)-stimulated EPC proliferation, migration, adhesion, in vitro tube formation were investigated. The results showed that Ang II (1 μM) enhanced EPC migration, adhesion, in vitro tube formation but had no effect on cell proliferation. Zol (75 and 100 μM) inhibited proliferation of EPCs and 50 μM geranylgeranyol (GGOH) could reverse the decrease of EPC proliferation. We found for the first time that Zol (50–100 μM) dose dependently attenuated migration, adhesion, and in vitro tube formation of EPCs stimulated by Ang II. GGOH could reverse the attenuation of EPC function induced by Zol. However, Zol did not induce EPC apoptosis. In addition, the underlying mechanisms were determined. The results revealed that Zol markedly down-regulated active RhoA stimulated by Ang II and inhibited the phosphorylation of Erk1/2 and JNK. Moreover, RhoA silencing resulted in a notable inhibition of EPC in vitro tube formation, suggesting that RhoA suppression played a pivotal role in Zol antiangiogenic effect. Conclusions/Significance These findings suggested that Zol attenuated the promotion of EPC function stimulated by Ang II and exhibited novel antiangiogenic effect via RhoA and MAPK signaling. Thus, Zol may be served as a novel therapeutic agent for neovascular-related diseases treatment.
References
[1]
Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–1763.
[2]
Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, et al. (2012) Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis. PLoS One 7: e33418.
[3]
Sata M (2006) Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol 26: 1008–1014.
[4]
Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, et al. (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 100: 4736–4741.
[5]
Khurana R, Simons M, Martin JF, Zachary IC (2005) Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 112: 1813–1824.
[6]
Sueishi K, Yonemitsu Y, Nakagawa K, Kaneda Y, Kumamoto M, et al. (1997) Atherosclerosis and angiogenesis. Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann N Y Acad Sci 811: 311–314, 311-322, 322-314.
[7]
Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, et al. (2002) Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105: 415–418.
[8]
Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221–228.
[9]
Li CX, Shao Y, Ng KT, Liu XB, Ling CC, et al. (2012) FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One 7: e32380.
[10]
Hu Y, Davison F, Zhang Z, Xu Q (2003) Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 108: 3122–3127.
[11]
Rumpold H, Wolf D, Koeck R, Gunsilius E (2004) Endothelial progenitor cells: a source for therapeutic vasculogenesis? J Cell Mol Med 8: 509–518.
[12]
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967.
[13]
Bleiziffer O, Hammon M, Naschberger E, Lipnik K, Arkudas A, et al. (2011) Endothelial progenitor cells are integrated in newly formed capillaries and alter adjacent fibrovascular tissue after subcutaneous implantation in a fibrin matrix. J Cell Mol Med 15: 2452–2461.
[14]
Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD (1998) Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800–807.
[15]
Mazzolai L, Duchosal MA, Korber M, Bouzourene K, Aubert JF, et al. (2004) Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension 44: 277–282.
[16]
Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, et al. (2011) Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 11: 405–411.
[17]
Lau ST, Leung PS (2011) Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 11: 412–420.
[18]
Ichiki T (2004) Role of renin angiotensin system in angiogenesis: it is still elusive. Arterioscler Thromb Vasc Biol 24: 622–624.
[19]
Kawada K, Minami H, Okabe K, Watanabe T, Inoue K, et al. (2005) A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Jpn J Clin Oncol 35: 28–33.
[20]
Gozzetti A, Gennari L, Merlotti D, Salvadori S, De Paola V, et al. (2008) The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 82: 258–262.
[21]
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, et al. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376: 1989–1999.
[22]
Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, et al. (2009) Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 151: 115–120.
[23]
Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T (2007) Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem 14: 2126–2135.
[24]
Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, et al. (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055–1061.
[25]
Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, et al. (2011) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14: 2803–2815.
[26]
Bryan BA, Dennstedt E, Mitchell DC, Walshe TE, Noma K, et al. (2010) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 24: 3186–3195.
[27]
Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, et al. (2004) The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 14: 29–41.
[28]
Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, et al. (2011) Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 300: C1181–1192.
[29]
Hong SY, Jeon YM, Lee HJ, Kim JG, Baek JA, et al. (2010) Activation of RhoA and FAK induces ERK-mediated osteopontin expression in mechanical force-subjected periodontal ligament fibroblasts. Mol Cell Biochem 335: 263–272.
[30]
Kahler CM, Wechselberger J, Hilbe W, Gschwendtner A, Colleselli D, et al. (2007) Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res 8: 50.
[31]
Chen JZ, Zhu JH, Wang XX, Xie XD, Sun J, et al. (2004) Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 36: 233–239.
[32]
Ye Y, Hu SJ, Li L (2009) Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway. FEBS Lett 583: 2997–3003.
[33]
Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605–1612.
[34]
Kwon YH, Jung SY, Kim JW, Lee SH, Lee JH, et al. (2012) Phloroglucinol inhibits the bioactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice. PLoS One 7: e33618.
[35]
Raikkonen J, Monkkonen H, Auriola S, Monkkonen J (2010) Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol 79: 777–783.
[36]
Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, et al. (2005) Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 15: 1–9.
[37]
Fournier PG, Stresing V, Ebetino FH, Clezardin P (2010) How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 12: 571–578.
[38]
Bifulco M (2005) Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci 77: 1740–1749.
[39]
Crick DC, Andres DA, Waechter CJ (1997) Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun 237: 483–487.
[40]
Merajver SD, Usmani SZ (2005) Multifaceted role of Rho proteins in angiogenesis. J Mammary Gland Biol Neoplasia 10: 291–298.
[41]
Bryan BA, D'Amore PA (2007) What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci 64: 2053–2065.
[42]
Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420: 629–635.
[43]
Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, et al. (2010) Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23: 861–867.
[44]
Huang D, Ding Y, Luo WM, Bender S, Qian CN, et al. (2008) Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 68: 81–88.
[45]
Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E, Rodriguez-Vita J, Rodrigues Diez R, et al. (2008) Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 25: 2447–2461.
[46]
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348: 593–600.
